The European Patent Office (EPO) has published a patent application, EP2026030234A2, detailing a gene therapy approach for treating cardiomyopathy-related diseases. The patent focuses on the use of ATF4 gene therapy and was published on March 18, 2026. The application lists multiple European countries as designated states.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in the biotechnology and pharmaceutical sectors related to cardiovascular disease treatment. Companies operating in this space should be aware of this patent filing as it may impact intellectual property landscapes and future research and development strategies.